Are you Dr. Wood?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
451 Junction Rd
Madison, WI 53717Phone+1 608-265-0700Fax+1 608-265-7759
Summary
- Dr. Gary Wood, MD is a board certified dermatologist in Madison, Wisconsin. He is currently licensed to practice medicine in Wisconsin, Ohio, and California. He is affiliated with University Hospital and William S. Middleton Memorial Veterans' Hospital.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Dermatology, 1983 - 1985- Stanford Health Care-Sponsored Stanford UniversityResidency, Pathology-Anatomic and Clinical, 1981 - 1982
Stanford Health CareInternship, Transitional Year, 1979 - 1980
University of Illinois College of MedicineClass of 1979
Certifications & Licensure
CA State Medical License 1981 - 2026
OH State Medical License 1989 - 2025
WI State Medical License 2001 - 2025- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
- American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Fellow (FAAD) American Academy of Dermatology
- Join now to see all
Clinical Trials
- Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Publications & Presentations
PubMed
- 1 citationsThe Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.Lei Zhao, Tony Hsiao, Connor Stonesifer, Jay Daniels, Tiffany J Garcia-Saleem
The Journal of Investigative Dermatology. 2022-12-01 - 20 citationsEfficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.Ellen J Kim, Aaron R Mangold, Jennifer A DeSimone, Henry K Wong, Lucia Seminario-Vidal
JAMA Dermatology. 2022-09-01 - 71 citationsPrimary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren C. Pinter-Brown, Francine M. Foss
Blood. 2021-11-10
Press Mentions
Total Skin Electron Radiation Used to Treat Rare CancerMarch 2nd, 2017
Grant Support
- Phase II Rhil-12 In MF With Cross-Over To Phase I IL-2 Administered With IL-12National Center For Research Resources2004–2006
- Translational Research &Mentoring In Cutaneous LymphomaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000–2003
- Phase I Trial Of 06 Benzylguanine &Bcnu In Cutaneous T Cell LymphomaNational Center For Research Resources2000–2002
- Translational Research &Mentoring In Cutaneous LymphomaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1999–2000
- Core--Cellular And Molecular MorphologyNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1994–1998
- Murine Model Of Cutaneous Lymphoid HyperplasiaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1997
- Treatment Of CTCL With O6 Benzylguanine/BcnuNational Cancer Institute1997
- HTLV-I Mycosis Fungoides/Sezary SyndromeNational Cancer Institute1994–1996
- Dendritic Cell Leukocyte Common AntigenNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1994–1995
- Analysis Of Dendritic Cell Leukocyte Common AntigenNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1991–1993
Professional Memberships
- Fellow
- Fellow
